BTIG Rates Serina Therapeutics (SER) buy, $8 Price Target
BTIG reaffirms its Buy rating for Serina Therapeutics with an $8 price target, a 312.37% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Serina Therapeutics, Inc. ($SER) "buy" with a $8 price target on July 1, 2026.
Since the rating, $SER is up 4.2% after 1 week, up 4.2% after 1 month and down 10.4% to date (from the $1.92 close on Jul 1, 2026).
SER
Serina Therapeutics, Inc.
Key Points
- BTIG reiterated a Buy rating for Serina Therapeutics, Inc. (SER) with a price target of $8 on July 1.
- BTIG's $8 price target implies 312.37% upside from Serina Therapeutics, Inc.'s ($SER) current $1.94 share price.
- Serina Therapeutics' stock traded at $1.94 on Wednesday, with a market cap of about $29.1 million and a 52-week range between $1.22 and $7.92.
- Insider buying was notable with Gregory Bailey acquiring over 8.4 million shares on June 17, indicating strong insider interest.
Get $SER trade alerts by text
We text you when insiders, Congress or big funds trade $SER. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Serina Therapeutics, Inc. alert may contain errors. Disclosures
BTIG reiterated its Buy rating on Serina Therapeutics, Inc. (NYSE American: SER) on July 1, maintaining a price target of $8. Analyst Thomas Shrader expressed continued confidence in the company's prospects.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Serina Therapeutics
SIO Capital Management, LLC opened a new position in Serina Therapeutics, acquiring 1,000,000 shares valued at approximately $1.94 million. Vanguard Capital Management LLC also initiated a stake, purchasing 159,136 shares worth around $308,724. Geode Capital Management, LLC increased its holdings by 34,564 shares, resulting in a total of 64,973 shares valued at $126,049, reflecting a 113.7% increase. BlackRock, Inc. significantly boosted its position by 41,015 shares, ending with 58,264 shares valued at $113,033, a 237.8% increase.
Serina Therapeutics, Inc. Stock Down 13.8%
Shares of NYSE American:SER traded at around $1.94 on Wednesday. Serina Therapeutics has a market capitalization of approximately $29.1 million. The stock has a 52-week low of $1.22 and a high of $7.92, with a 50-day moving average of $1.84 and a 200-day moving average of $2.89. The company's current ratio stands at 4.18, and the debt-to-equity ratio is 18.93, indicating a strong liquidity position.
$SER price target
Serina Therapeutics, Inc. daily closes and this analyst's $8 target. Not advice.
Recent Earnings
Serina Therapeutics reported revenue of $130,000, with no net margin due to ongoing investments in research and development. The company recorded a negative return on equity of -2.22%. The next earnings report is expected on August 4, 2025.
Insider Buying and Selling at Serina Therapeutics, Inc.
On June 17, several insiders made significant purchases of Serina Therapeutics stock. Gregory Bailey acquired 8,437,472 shares, while Jay Venkatesan bought 224,152 shares at an average price of $2.25. Other insiders, including Karen Wilson and Richard Peter Marshall, also participated in the buying spree, each acquiring 15,250 shares.
Analysts Set New Price Targets
On July 1, BTIG reiterated its Buy rating for Serina Therapeutics with an $8 price target. HC Wainwright & Co. had previously set a Buy rating with a $15 target on August 28, 2025. Jones Trading also initiated coverage with a Buy rating and an $11 target on March 11, 2025. Currently, the consensus target price is $11, based on one analyst's opinion.
About Serina Therapeutics
Serina Therapeutics, Inc. is a biotechnology company focused on developing treatments for neurological diseases and pain. Its lead product, SER 252, is in phase 1 clinical trials for advanced Parkinson's disease. The company also explores POZ technology for lipid nanoparticle vaccines. Founded in 2006, Serina Therapeutics is headquartered in Huntsville, Alabama, and led by CEO Steven A. Ledger.
Bottom Line
BTIG's reaffirmation of a Buy rating with an $8 target reflects confidence in Serina Therapeutics' potential. Investors watch analyst ratings for insights, though it's important to remember these are forward-looking estimates. As always, 13F filings and analyst opinions are backward-looking and may not reflect current conditions.
Related Filing Alerts
Source: BTIG's rating change on $SER (Jul 1, 2026). Written by software, not financial advice. How we make alerts